Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mochida Pharmaceutical Co., Ltd. (4534.T)
Tokyo, JP
Established in 1913 and headquartered in Tokyo, Japan, Mochida Pharmaceutical Co., Ltd. specializes in the development, manufacturing, and distribution of a wide array of medical and personal care products. Its primary offerings encompass pharmaceuticals, diagnostic solutions, and skincare lines. The company's extensive pharmaceutical portfolio includes treatments for a variety of conditions, such as cardiovascular issues, pain (analgesics), gastrointestinal ailments, neurological disorders, infections (anti-infectives), diabetes (antidiabetics), and cancer (oncological agents). Additionally, it provides hormone and biological preparations, alongside biosimilars, catering to therapeutic areas like dermatology, psychiatry, obstetrics, and gynecology. In diagnostics, Mochida produces various reagents, particularly those utilized for fertility and infertility assessments. Its skincare division features products designed for facial, body, and hair care. Beyond its existing product range, Mochida Pharmaceutical actively invests in research and development, with a specific focus on creating therapies for intractable diseases. The company has also forged strategic collaborations, including a partnership with Amarin Corporation plc for the advancement and market introduction of ethyl icosapentate products. Furthermore, it collaborates with Gene Techno Science Co., Ltd. to innovate regenerative medicine targeting rare and challenging digestive disorders, such as congenital isolated hypoganglionosis.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.15% | +3.83% | -1.95% | -8.44% | +6.33% | -0.42% | +18.49% | -3.29% | -5.75% | -7.60% | +100.57% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+11.2% ★ Q1'26: +20.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+39.0% ★ Q1'26: +1,848.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-9.8% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+8.7% Q1'26: +8.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+6.0% Q1'26: +5.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.76× ★ Q1'26: 0.73× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
87.25B
est: 87.20B (+0.1%)
|
92.27B
est: 90.00B (+2.5%)
|
97.35B
est: 85.50B (+13.9%)
|
106.75B
est: 82.90B (+28.8%)
|
109.65B
est: 111.50B (-1.7%)
|
101.80B
est: 101.70B (+0.1%)
|
103.00B
est: 102.50B (+0.5%)
|
110.18B
est: 109.50B (+0.6%)
|
103.26B
est: 106.50B (-3.0%)
|
102.89B
est: 102.00B (+0.9%)
|
105.16B
est: 106.00B (-0.8%)
|
108.00B
108.00B – 108.00B
+1.9% YoY
|
110.00B
110.00B – 110.00B
+1.9% YoY
|
| EBITDA |
14.70B
est: 10.55B (+39.2%)
|
14.92B
est: 10.89B (+36.9%)
|
14.11B
est: 10.35B (+36.3%)
|
14.28B
est: 10.03B (+42.3%)
|
13.51B
est: 13.50B (+0.1%)
|
11.54B
est: 12.31B (-6.3%)
|
14.75B
est: 12.41B (+18.9%)
|
17.08B
est: 13.25B (+28.9%)
|
11.18B
est: 12.89B (-13.3%)
|
8.61B
est: 12.15B (-29.1%)
|
11.07B
est: 11.97B (-7.5%)
|
12.19B
12.19B – 12.19B
+1.9% YoY
|
12.42B
12.42B – 12.42B
+1.9% YoY
|
| EBIT |
11.69B
est: 8.25B (+41.7%)
|
12.15B
est: 8.52B (+42.7%)
|
11.37B
est: 8.09B (+40.6%)
|
11.66B
est: 7.84B (+48.7%)
|
10.59B
est: 10.55B (+0.4%)
|
8.81B
est: 9.62B (-8.5%)
|
12.00B
est: 9.70B (+23.8%)
|
14.39B
est: 10.36B (+38.9%)
|
8.51B
est: 10.08B (-15.6%)
|
5.80B
est: 9.45B (-38.6%)
|
8.13B
est: 9.19B (-11.6%)
|
9.36B
9.36B – 9.36B
+1.9% YoY
|
9.54B
9.54B – 9.54B
+1.9% YoY
|
| Net Income |
7.54B
est: 6.69B (+12.7%)
|
8.15B
est: 6.78B (+20.1%)
|
8.53B
est: 6.29B (+35.5%)
|
9.02B
est: 5.89B (+53.2%)
|
8.44B
est: 7.48B (+12.8%)
|
4.60B
est: 4.09B (+12.4%)
|
8.59B
est: 7.09B (+21.1%)
|
10.57B
est: 8.86B (+19.3%)
|
6.65B
est: 6.83B (-2.6%)
|
4.55B
est: 4.39B (+3.5%)
|
5.69B
est: 5.89B (-3.5%)
|
6.64B
6.64B – 6.64B
+12.7% YoY
|
7.38B
7.38B – 7.38B
+11.3% YoY
|
| SGA |
29.88B
est: 29.53B (+1.2%)
|
29.39B
est: 30.47B (-3.5%)
|
29.71B
est: 28.95B (+2.6%)
|
29.99B
est: 28.07B (+6.8%)
|
30.58B
est: 37.75B (-19.0%)
|
31.23B
est: 34.44B (-9.3%)
|
31.94B
est: 34.71B (-8.0%)
|
32.87B
est: 37.08B (-11.4%)
|
33.32B
est: 36.06B (-7.6%)
|
33.71B
est: 32.27B (+4.5%)
|
33.99B
est: 35.32B (-3.8%)
|
35.99B
35.99B – 35.99B
+1.9% YoY
|
36.66B
36.66B – 36.66B
+1.9% YoY
|
| EPS |
188.63
est: 188.80 (-0.1%)
|
205.22
est: 191.35 (+7.2%)
|
214.72
est: 177.50 (+21.0%)
|
227.25
est: 166.15 (+36.8%)
|
212.86
est: 211.00 (+0.9%)
|
117.55
est: 115.40 (+1.9%)
|
222.27
est: 200.00 (+11.1%)
|
277.39
est: 249.90 (+11.0%)
|
178.93
est: 192.60 (-7.1%)
|
126.79
est: 123.90 (+2.3%)
|
160.36
est: 166.10 (-3.5%)
|
187.20
187.20 – 187.20
+12.7% YoY
|
208.30
208.30 – 208.30
+11.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 2/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 2/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 2/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 2/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.08% | 296.3K | 0.58% |
| 2 | iShares International Small-Cap Equity Factor ETF ISCF | 0.06% | 398.0K | 0.24% |
| 3 | State Street SPDR S&P International Small Cap ETF GWX | 0.04% | 382.8K | 0.40% |
| 4 | iShares MSCI Japan Small-Cap ETF SCJ | 0.04% | 93.4K | 0.50% |
| 5 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.03% | 164.7K | 0.58% |
| 6 | Schwab Fundamental International Small Company Index ETF FNDC | 0.02% | 551.4K | 0.39% |
| 7 | Schwab International Small-Cap Equity ETF SCHC | 0.02% | 900.4K | 0.06% |
| 8 | Avantis International Small Cap Equity ETF AVDS | 0.02% | 52.5K | 0.30% |
| 9 | Dimensional - International Small Cap Value ETF DISV | 0.01% | 709.8K | 0.42% |
| 10 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.71M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hitoshi Mizuno | Managing Executive Officer & GM of Medical Device Product Development | — | — |
| Junichi Makino | Executive Officer Deputy Head of Pharmaceutical Sales Division | — | — |
| Junichi Sakaki | Senior Executive Managing Officer & Representative Director | — | male |
| Kenji Miyajima | Director & Managing Executive Officer | — | — |
| Masaaki Yokosuka | Executive Officer and Legal & Compliance Manager | — | — |
| Motoi Mitsuishi | Senior Executive Managing Officer & Representative Director | — | — |
| Naoyuki Mochida | President & Chairperson | — | male |
| Taiji Hayano | GM of Pharmaceutical Development Division & Managing Executive Officer | — | — |
| Tomokazu Matsusue | Managing Executive Officer & Head of Business Development Division | — | — |
| Yutaka Kawakami | Managing Executive Officer & Executive Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4534.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
